Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Financing Activities: 2015-2025

Historic Cash from Financing Activities for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to -$38,000.

  • Cartesian Therapeutics' Cash from Financing Activities fell 100.03% to -$38,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.2 million, marking a year-over-year decrease of 103.97%. This contributed to the annual value of $168.4 million for FY2024, which is 1381.31% up from last year.
  • Cartesian Therapeutics' Cash from Financing Activities amounted to -$38,000 in Q3 2025, which was down 163.33% from $60,000 recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Cash from Financing Activities high stood at $124.5 million for Q3 2024, and its period low was -$24.8 million during Q3 2023.
  • Its 3-year average for Cash from Financing Activities is $13.4 million, with a median of $120,000 in 2024.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 4,150.49% in 2023, then soared by 28,779.87% in 2024.
  • Cartesian Therapeutics' Cash from Financing Activities (Quarterly) stood at $21.2 million in 2021, then tumbled by 57.79% to $612,000 in 2022, then tumbled by 4,150.49% to $14.1 million in 2023, then plummeted by 94.44% to $783,000 in 2024, then tumbled by 100.03% to -$38,000 in 2025.
  • Its Cash from Financing Activities was -$38,000 in Q3 2025, compared to $60,000 in Q2 2025 and -$8.0 million in Q1 2025.